Loading
NASDAQHealthcareMedical - Pharmaceuticals
Latest quote
$10.72
+$0.21 · +2.00%
Helus Pharma is a clinical-stage pharmaceutical company developing proprietary serotonergic agonists for mental health conditions. Its pipeline includes HLP003, in Phase 3 development for adjunctive treatment of major depressive disorder, and HLP004, in Phase 2 development for generalized anxiety disorder.
Previous close
$10.72
+$0.21 · +2.00%
After-hours
$10.77
+$0.05 · +0.47%
Oct 8, 7:57 PM ET
Regular session · ET · Market data may be delayed.
Helus Pharma is a clinical-stage pharmaceutical company developing proprietary serotonergic agonists for mental health conditions. Its pipeline includes HLP003, in Phase 3 development for adjunctive treatment of major depressive disorder, and HLP004, in Phase 2 development for generalized anxiety disorder.
Day range
Current $10.72
52-week range
Current $10.72
Regular session · ET · Market data may be delayed.
GoAI Score
Sell
Valuation
22
Expensive
Sentiment
45
Mixed
Risk
52
Elevated Risk
Momentum
64
Gaining
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
Helus Pharma is a clinical-stage pharmaceutical company developing proprietary serotonergic agonists for mental health conditions. Its pipeline includes HLP003, in Phase 3 development for adjunctive treatment of major depressive disorder, and HLP004, in Phase 2 development for generalized anxiety disorder.
Day range
Current $10.72
52-week range
Current $10.72
Profitability as a percentage of reported revenue.
Revenue
Operating income
Net income
| Metric (USD) | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|---|
| Revenue | −44.68M USD | 472.27K USD | — | 251.02K USD | 167.76K USD |
| Cost of goods sold | 119.23K USD | 472.27K USD | — | 251.02K USD | 167.76K USD |
| Gross profit | −44.8M USD | — | — | — | — |
| Research and development | 86.04M USD | 54.91M USD | 32.36M USD | 25.49M USD | 17.59M USD |
| Selling, general, and administrative | 56M USD | 88.24M USD | 46.47M USD | 26.03M USD | 46.25M USD |
| Operating expenses | 96.87M USD | 143.15M USD | 78.84M USD | 51.52M USD | 63.84M USD |
| Interest income | 5.07M USD | 8.29M USD | 619K USD | 603K USD | 241K USD |
| Depreciation and amortization | 120K USD | 472.27K USD | 424K USD | 251K USD | 168K USD |
| Operating income | −141.68M USD | −143.15M USD | −78.84M USD | −51.52M USD | −63.84M USD |
| Net income | −147.05M USD | −113.14M USD | −78.08M USD | −47.49M USD | −67.63M USD |
Company facts updated Oct 9, 2026.
Recent quarterly results
Third-party consensus; not a GoAI recommendation.
Limited analyst sample: 4 ratings. Interpret the distribution with caution.
Funds reporting this stock among their holdings, ordered by reported position size.
AdvisorShares Psychedelics ETFPSIL3.86M8.48%48.22M USD1.84%$20.99-0.80%
Fidelity Nasdaq Composite Index ETFONEQ324.05K—10.94B USD0.21%$107.13-1.22%
State Street SPDR S&P International Small Cap ETFGWX312.87K0.03%917.55M USD0.40%$45.14-0.75%
Invesco NASDAQ Future Gen 200 ETFQQQS107.18K0.47%22.71M USD0.20%$41.5683-1.09%
T. Rowe Price Innovation Leaders ETFTNXT9.4K0.05%19.66M USD0.49%$28.8038-0.98%AdvisorShares Psychedelics ETFPSILFidelity Nasdaq Composite Index ETFONEQState Street SPDR S&P International Small Cap ETFGWXInvesco NASDAQ Future Gen 200 ETFQQQST. Rowe Price Innovation Leaders ETFTNXTAI-generated and delayed market data for informational and educational purposes only. Not investment advice.
